Compounds for four additional tropical diseases are now eligible to receive Priority Review vouchers upon FDA approval. FDA expanded its list of diseases eligible for the program on Thursday to include Chikungunya, rabies, cryptococcal meningitis and Lassa fever.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,